Autoimmune disorders exhibit intricate pathology. Their mechanisms are complex, which attenuates the need for novel therapeutic interventions. Frexalimab, a potent monoclonal antibody targeting the dysregulated CD40-CD40L pathway, stands out as a formidable weapon against the assault of inflammation and tissue devastation. Diverse electronic databases were searched using relevant keywords to extract data on the role of Frexalimab in combating various autoimmune diseases. This review highlights Frexalimab’s efficacy in improving various disability indicators of relapsing multiple sclerosis (RMS), alleviating fatigue in primary Sjögren’s syndrome (PSJS), and improving glycemic control in diabetic patients. Across multiple trials, its favorable safety profile has proven its superiority over first-generation drugs in minimizing side effects. Indeed, Frexalimab has become a harbinger of hope in the fight against autoimmune diseases and has pioneered a unique and unchallenging way for tackling complex autoimmune diseases in the clinical realm, however, further large-scale trials are needed to establish its therapeutic benefits across different autoimmune conditions.

Heart failure (HF) and diabetes mellitus frequently co-occur, with an incidence of HF among diabetics ranging from 9% to 22%. Clinical research underscores that shared pathophysiological pathways link these conditions, driving advancements in therapeutic strategies that target neuro-hormonal modulation and sodium-glucose co-transporter 2 (SGLT2) inhibition. The SOLOIST-WHF and SCORED trials highlighted the efficacy of sotagliflozin, a dual sodium-glucose co-transporters 1/2 (SGLT1/2) inhibitor, in patients with HF and chronic kidney disease (CKD), demonstrating reductions in cardiovascular mortality and HF-related hospitalizations. Trials with other SGLT2 inhibitors, like dapagliflozin and empagliflozin, in HF, diabetes, and renal disease also showed significant reductions in major adverse cardiovascular events, hospitalizations, and improved kidney function. Furthermore, SGLT2 inhibitors have shown neuroprotective effects, potentially benefiting patients with Alzheimer’s and Parkinson’s diseases. Dual SGLT1/2 inhibitors, by targeting glucose transport in the renal and intestinal systems, not only reduce blood glucose but also improve insulin sensitivity, weight loss, and cardiovascular health. Sotagliflozin specifically impacts postprandial glucose absorption, mitigating the risks of hypoglycemia and hyperglycemia-related complications. In diabetic CKD, SGLT inhibitors promote renal protection by reducing glucose reabsorption, diuresis, and systemic inflammation. Neuroprotective effects of these agents, including reduced oxidative stress and inflammatory markers, show promise in treating neurodegenerative diseases. While adverse effects like hypoglycemia and ketoacidosis remain concerns, tailored dosing, and monitoring strategies may mitigate these risks. Thus, SGLT inhibitors, especially dual inhibitors like sotagliflozin, offer broad therapeutic benefits in diabetes, HF, CKD, and potentially neurological conditions.

Mitral regurgitation (MR) is the most prevalent valvular heart disease in developed countries, particularly affecting the elderly population. In its severe, untreated form, MR is associated with high morbidity and mortality. Current therapeutic approaches include pharmacological management, surgical interventions, and emerging transcatheter mitral valve repair (TMVR) techniques. While medical therapy provides symptomatic relief, it lacks disease-modifying effects in advanced cases. Surgical repair or replacement remains the gold standard; however, it is often unsuitable for high-risk or inoperable patients. TMVR has emerged as a transformative, minimally invasive alternative, offering improved outcomes with reduced procedural risks. Devices such as MitraClip, Cardio band, and other novel TMVR technologies have demonstrated encouraging results in clinical trials, improving survival rates and quality of life. Despite its advantages, challenges such as anatomical variability, device durability, and long-term efficacy remain. With continuous technological advancements, optimized patient selection, and collaborative efforts in research and innovation, TMVR is poised to revolutionize the management of MR, bridging the gap between conventional surgery and medical therapy. This editorial explores the current landscape, benefits, limitations, and future directions of TMVR in the treatment of MR.

Objectives: Pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor, was developed to overcome resistance mutations that limit covalent BTK inhibitors and to offer improved tolerability. Three phase III randomized trials (BRUIN CLL-321, CLL-313, and CLL-314) have evaluated pirtobrutinib against distinct comparators in different chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) populations, but no pooled evidence exists, as of now. Methods: Following PRISMA 2020 guidance for systematic reviews without meta-analysis, we searched Embase, Scopus, and PubMed from inception to July 2026 for double-arm randomized trials of pirtobrutinib in CLL/SLL. We extracted safety and efficacy data from the trials and synthesized it narratively. Results: Of 500 identified records, 3 trials met eligibility criteria. In relapsed/refractory patients previously treated with a covalent BTK inhibitor (CLL-321), pirtobrutinib reduced progression or death by 46% versus investigator’s-choice therapy (HR: 0.54). In treatment-naive patients (CLL-313), pirtobrutinib reduced risk by 80% versus bendamustine-rituximab (HR: 0.20). In CLL-314, pirtobrutinib was noninferior to ibrutinib on objective response rate (87.0% vs. 78.5%) with a favorable early progression-free survival trend (HR: 0.57). Overall survival data remained inconclusive across trials, complicated by substantial crossover. Importantly, pirtobrutinib consistently showed lower rates of grade ≥3 adverse events, discontinuations, and cardiovascular toxicity, including markedly reduced atrial fibrillation versus ibrutinib. Conclusions: Pirtobrutinib demonstrates consistent efficacy and a favorable safety profile across relapsed/refractory and treatment-naive CLL/SLL settings, with the strongest evidence in patients who progressed on covalent BTK inhibitors. However, longer follow-up and head-to-head comparisons with other covalent inhibitors are warranted to establish its frontline role in this population.

Alcohol-induced liver disease, encompassing steatosis, hepatitis, cirrhosis, and liver failure, is a significant global health burden, affecting 10–35% of individuals with alcohol use disorder. Alcoholic hepatitis, characterized by hepatocyte inflammation due to chronic alcohol consumption, arises from toxic intermediates produced during alcohol metabolism. These intermediates disrupt cellular function, trigger immune responses, and promote fibrosis, leading to cirrhosis and liver failure. Despite current treatments like corticosteroids and liver transplantation, which alleviate symptoms but fail to reverse cellular damage, the rising prevalence of alcoholic hepatitis underscores the urgent need for innovative therapies. Larsucosterol, a novel epigenetic modulator, has emerged as a promising candidate. By inhibiting DNA methyltransferase, larsucosterol reduces DNA hypermethylation and modulates genes involved in inflammation, lipid metabolism, and cell survival, thereby mitigating liver damage. Early-phase clinical trials, including a phase 2a study, demonstrated its safety, tolerability, and improved biochemical parameters in patients. However, the phase 2b AHFIRM trial did not achieve its primary endpoint, though a lower mortality rate in the 30 mg group suggests potential benefits requiring further investigation. Larsucosterol’s immunomodulatory and anti-inflammatory properties offer advantages over corticosteroids, particularly in patients unresponsive to standard therapies. Despite its promise, limitations such as the need for larger, more diverse trials, long-term safety data, and exploration of combination therapies remain. In conclusion, larsucosterol represents a groundbreaking approach to treating alcoholic hepatitis, but extensive research is essential to fully establish its therapeutic potential and address existing gaps in knowledge.